Healthcare >> Sector Roundtables >> January 26, 2004
DOUGLAS LOE is healthcare and biotechnology analyst at Dlouhy Merchant
Group. Dr. Loe has covered the Canadian biotechnology sector since 2000
and joined the Dlouhy team in August 2002. He holds a MBA from Queen's
University and a PhD in biochemistry from the University of Guelph,
working in the area of cancer chemotherapy and multidrug resistance,
followed by post-doctoral training at the Queen's University Cancer
Research Laboratories. Prior to commencing his career in financial
analysis, Dr. Loe worked as a consultant to Molecular Mining Corporation
and MDS Inc. To date, Dr. Loe has published 24 abstracts and 17 peer-
reviewed manuscripts and review articles related to P-glycoprotein and
MRP-mediated multidrug resistance. Profile
BARBARA A. JOHNSTON has been a Life Sciences Analyst with Haywood
Securities Inc. in Vancouver, British Columbia, since 2000. In this
position, Dr. Johnston assesses both private and public biotechnology
and healthcare companies for investment opportunities. She also
researches and evaluates value and growth prospects for private biotech
and medical device companies. Prior to joining Haywood Securities, Dr.
Johnston served for a year as the Associate Director of Professional
Services at Charles River Laboratories in Wilmington, Massachusetts. In
this role, she professionally oversaw the world's largest research
animal diagnostic laboratory. Before that, Dr. Johnston spent 12 years
as the Vavarium Director of Animal Health Resources at the Fred
Hutchinson Cancer Research Center in Seattle. Dr. Johnston received her
board certification from the American College of Laboratory Animal
Science in 1994 after performing her residency in Laboratory Animal
Medicine at the University of Washington. She received her Doctorate in
Veterinary Medicine from Washington State University in 1985, after
completing her bachelor's degree in Biology and Fisheries from the
University of Washington in 1981. Profile
market perspective?
Dr. Johnston: The sector as a whole did well in North America, and I
think that Canadian biotech has
